Prothena earnings missed by $0.11, revenue fell short of estimates
Prothena (PRTA) reported Q3 EPS of -$0.32, missing estimates by $0.11, with revenue of $620K, below the $9.59M consensus. The stock is down 9.93% over 3 months and 25.28% over 12 months. InvestingPro rates its financial health as 'good performance'.
How this was made
The 30-second read
Why it matters
The earnings shortfall is likely to trigger a sell‑off, especially given the large revenue miss relative to expectations.
Market read
The news is relevant for traders focused on biotech micro‑caps and earnings‑driven price moves.
What to watch
Potential upcoming clinical trial data or partnership announcements not covered in this release.
Background
Prothena (NASDAQ: PRTA) is a small‑cap biotech company. The article reports its third‑quarter earnings, which missed consensus estimates.
Ticker impact
Prothena reported Q3 EPS of -$0.32, missing estimates by $0.11 and revenue of $620K versus $9.59M consensus.
likely pressure as the market prices in the earnings shortfall
Both EPS and revenue fell short of expectations, which typically triggers a sell-off for a micro‑cap biotech.
Market effects
Biotech sector may see modest pullback as earnings miss highlights revenue volatility.
Limited to US-listed micro‑cap biotech investors.
Low global relevance; impact confined to niche investors.
Counterpoint
If the miss is viewed as a temporary setback and pipeline progress remains strong, the stock could be a buying opportunity at lower levels.
Key entities
- companyProthena
Biotech firm reporting Q3 results.
